Literature DB >> 24470499

Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response.

Patrick Bartholomaeus1, Linda Y Semmler, Thomas Bukur, Valesca Boisguerin, Paula S Römer, Paula Tabares, Sergey Chuvpilo, Dmitry Y Tyrsin, Alexey Matskevich, Hartmut Hengel, John Castle, Thomas Hünig, Ulrich Kalinke.   

Abstract

Following inconspicuous preclinical testing, the superagonistic anti-CD28 mAb TGN1412 was applied to six study participants who all developed a devastating cytokine storm. We verified that TGN1412 treatment of fresh PBMCs induced only moderate responses, whereas restoration of tissue-like conditions by high-density preculture (HDC) allowed vigorous cytokine production. TGN1412 treatment of T cells isolated from HDC-PBMCs induced moderate cytokine responses, which upon additional anti-IgG crosslinking were significantly boosted. Moreover, coincubation of TGN1412-treated T cells with B cells expressing the intermediate affinity Fcγ receptor IIB (CD32B), or coincubation with CD32B(+) transfectants, resulted in robust T cell activation. This was surprising because TGN1412 was expressed as an Ig of the subclass 4 (IgG4), which was shown before to exhibit only minor affinity to FcγRs. Transcriptome analysis of TGN1412-treated T cells revealed that similar gene signatures were induced irrespective of whether T cells derived from fresh or HDC-PBMCs were studied. Collectively, these data indicate that HDC-PBMCs and HDC-PBMC-derived T cells mount rapid TGN1412 responses, which are massively boosted by FcγR crosslinking, in particular by CD32-expressing B cells. These results qualify HDC-PBMCs as a valuable in vitro test system for the analysis of complex mAb functions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24470499     DOI: 10.4049/jimmunol.1302461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.

Authors:  Sandrine Vessillier; Madeline Fort; Lynn O'Donnell; Heather Hinton; Kimberly Nadwodny; Joseph Piccotti; Peter Rigsby; Karin Staflin; Richard Stebbings; Divya Mekala; Aarron Willingham; Babette Wolf
Journal:  Cytokine X       Date:  2020-12

Review 2.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

3.  Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.

Authors:  Hong Xu; Ming Cheng; Hongfen Guo; Yuedan Chen; Morgan Huse; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2014-12-26       Impact factor: 11.151

Review 4.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

5.  Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

Authors:  Ann L White; H T Claude Chan; Ruth R French; Jane Willoughby; C Ian Mockridge; Ali Roghanian; Christine A Penfold; Steven G Booth; Ali Dodhy; Marta E Polak; Elizabeth A Potter; Michael R Ardern-Jones; J Sjef Verbeek; Peter W M Johnson; Aymen Al-Shamkhani; Mark S Cragg; Stephen A Beers; Martin J Glennie
Journal:  Cancer Cell       Date:  2014-12-11       Impact factor: 31.743

Review 6.  Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.

Authors:  Richard J Stopforth; Kirstie L S Cleary; Mark S Cragg
Journal:  J Clin Immunol       Date:  2016-02-27       Impact factor: 8.317

7.  Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

Authors:  S Vessillier; D Eastwood; B Fox; J Sathish; S Sethu; T Dougall; S J Thorpe; R Thorpe; R Stebbings
Journal:  J Immunol Methods       Date:  2015-05-07       Impact factor: 2.303

8.  Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells.

Authors:  Stephanie Vogel; Elena Grabski; Daniela Buschjäger; Frank Klawonn; Marius Döring; Junxi Wang; Erika Fletcher; Ingo Bechmann; Torsten Witte; Martin Durisin; Burkhart Schraven; Sara M Mangsbo; Kurt Schönfeld; Niklas Czeloth; Ulrich Kalinke
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

9.  TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.

Authors:  Sabrina Weißmüller; Stefanie Kronhart; Dorothea Kreuz; Barbara Schnierle; Ulrich Kalinke; Jörg Kirberg; Kay-Martin Hanschmann; Zoe Waibler
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

Review 10.  Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Authors:  Christopher Paluch; Ana Mafalda Santos; Consuelo Anzilotti; Richard J Cornall; Simon J Davis
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.